Ronald Drengler is an Oncology physician affiliated with South Texas Accelerated Research Therapeutics. OpenAlex indexes 66 publications with 1,679 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4383 Medical Dr
San Antonio, TX 782293307
Telephone
210-593-5700Registry record last updated 11 Jul 2013.
Clinical trials
- Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors
Sponsor: The University of Texas Health Science Center at San Antonio
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
58 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202512 payments
- Galvanize Therapeutics, IncProgram year20251 payment
- Celgene CorporationProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.1%PD-1 inhibitor36.9%Nivolumab78%Pembrolizumab22%Part B, office-administered≥38 patientsPlatinum-based Drug13.6%Oxaliplatin98%Cisplatin1%Carboplatin1%Part B, office-administered≥22 patients+ 12 more classes in this area
Metabolism & gastrointestinal
13.9%Other antiemetics7.5%Fosaprepitant100%Part B, office-administered≥40 patientsSubstance P/Neurokinin-1 Receptor Antagonist2.2%Aprepitant100%Part B, office-administered≥16 patients+ 7 more classes in this area
Blood & clotting
9.7%Iron, parenteral preparations9.6%Ferric carboxymaltose92%Ferric derisomaltose8%Part B, office-administered≥18 patientsOsmotic Diuretic0%Mannitol100%Part B, office-administered≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
Clinical Cancer Research
2026 - Longitudinal ctDNA monitoring for post-surgical molecular residual disease in patients with stage I-IIIb melanoma.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”